Iron ion coupled mitoxantrone nanoparticle as well as preparation method and medical application thereof

The coordinated self-assembly of iron salt and mitoxantrone formed 40nm iron ion coupled mitoxantrone nanoparticles, which solved the problems of large doses and low bioavailability of iron ions and mitoxantrone in tumor treatment, and improved the The tumor targeting and penetration ability are greatly enhanced, and the inhibitory effect on tumors in deep hypoxic areas is significantly enhanced.

CN118924686APending Publication Date: 2024-11-12THE CENTRAL HOSPITAL OF WUHAN (WUHAN NO 2 HOSPITAL WUHAN CANCER RESEARCH INSTITUTE)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410149405.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-11-23
Filing Date
2024-02-02
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

In the prior art, iron ions are used for tumor treatment with high doses and high toxic side effects, mitoxantrone has low bioavailability and poor tumor penetration ability. The existing carrier technology has problems with low drug loading and repeatability, which is difficult to Effectively reach deep tumors in hypoxic areas.

Method used

40nm iron-ion-coupled mitoxantrone nanoparticles are formed by self-assembly of coordination between iron salt and mitoxantrone or its salt. The nanostructure with specific shapes and functions is constructed using coordination self-assembly technology to improve tumor targeting Sex and penetration ability.

Benefits of technology

It achieves better tumor targeting, accumulation and distribution than free drugs, has better tumor penetration ability and tumor inhibition effect, and reduces toxic side effects, especially in deep tumor sites in hypoxic areas. Proliferation inhibitory ability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004695099190000011
    Figure HDA0004695099190000011
  • Figure HDA0004695099190000012
    Figure HDA0004695099190000012
  • Figure HDA0004695099190000021
    Figure HDA0004695099190000021
Patent Text Reader

Abstract

The invention provides an ultra-small iron ion coupled mitoxantrone nanoparticle as well as a preparation method and medical application thereof. Specifically, a one-pot method is adopted for preparation, and the prepared iron ion coupled mitoxantrone nanoparticles are stable in property, show better tumor targeting, accumulation and distribution than free drugs, and have better tumor penetrating ability and tumor inhibition ability.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biomedicine, in particular to nanomedicine, and specifically to an iron ion coupled mitoxantrone nanoparticle, a preparation method thereof and medical use thereof. Background Art

[0002] Fenton reaction is an iron-dependent oxidation process, which has been widely used in previous studies to increase oxidative stress in cancer cells. In addition, in recent years, iron ions have also been shown to trigger a new type of cell death, namely ferroptosis of cancer cells. "Ferroptosis" is a new type of cell death proposed by Dxion in 2012. It can mediate the accumulation of intracellular lipid peroxides (LPO) to the ferritin death level and ultimately induce cell death. Its essence is a new type of cell oxidative death (Dixon S, Lemberg K, Lamprecht M, et al. Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death [J]. Cell, 2012 (5), 149.). In addition, iron compounds can also participate in the intracellular Fenton reaction, produce a large amount of reactive oxygen species (ROS) and insert into the lipid membrane to form LPO, thereby efficiently mediating ferroptosis (Hofmans S, Berghe TV, Devissacher L, et al. Novel ferroptosis inhibitors with improved potency and ADME properties [J]. Journal of Medicinal Chemistry, 2015 (5): 2041-53). The main mechanism of ferroptosis is that under the action of divalent iron or ester oxygenase, unsaturated fatty acids on the cell membrane are catalyzed to cause lipid peroxidation, thereby inducing cell death; in addition, the activity of glutathione peroxidase 4 (GPX4) in the antioxidant system is also reduced. However, the dosage required for iron compounds for tumor treatment is large and the risk of toxic side effects is high, so its use is limited.

[0003] Mitoxantrone (MIT) is one of the first-line anticancer drugs for the treatment of various cancers. However, clinical applications have revealed several shortcomings of mitoxantrone, including low bioavailability and potential organ cell toxicity. To address these problems, existing technology studies have proposed some carrier technologies, including polymer micelles, liposomes, inorganic and organic-inorganic hybrid nanoparticles, in an attempt to improve their bioavailability and reduce toxic side effects. However, existing carrier technologies still have problems with low drug loading and repeatability, and low tumor penetration ability, so that drugs cannot reach deeper tumor areas away from blood vessels such as hypoxia, resulting in poor efficacy.

[0004] Prior art 1 (CN201910084885.0, publication number CN109806252A) adopts a ternary composite nanosystem of an iron compound, a small molecule anti-tumor active compound containing a benzene ring, and a polyphenol compound, which overcomes the drug resistance problem of the small molecule anti-tumor active compound containing a benzene ring, but it does not have the ability to deliver deep into tumors, especially the ability to penetrate tumor tissues, which may be due to its inappropriate particle size.

[0005] Prior art 2 (CN202311023969.6, publication number CN116898875A) discloses a nanodrug formed by coordination self-assembly of an iron salt and mitoxantrone dihydrochloride. The average particle size of the nanodrug is 1-5 nm. Prior art 2 points out that nanodrugs of this particle size are more easily enriched in tumor tissues, but there is no data in the article to prove the effect of this technology, and there is no report on the ability of the nanodrug to deliver deep into tumors, especially the ability to penetrate tumor tissues.

[0006] Since tumors grow significantly faster than normal tissues, there are defects between tumor vascular endothelial cells, which are not tightly arranged and permeable, and the lymphatic drainage inside the tumor is insufficient, and the blood flow rate is low. Once nanoparticles enter, they will be retained in the tumor site. This phenomenon is called the EPR (enhanced permeability and retention) effect. Since the EPR effect was reported in the late 1980s, it has been recognized as the main factor for the enrichment of nanoparticles in tumor sites, that is, nanomedicines with a specific particle size range will be significantly enriched in tumor sites. However, in 2020, the Warren CW Chan team at the University of Toronto (Existing Technology 3: Sindhwani S, Syed AM, Ngai J, et al. The entry of nanoparticles into solid tumors. Nat Mater. 2020; 19 (5): 566-575. doi: 10.1038 / s41563-019-0566-2) explored the tumor penetration phenomenon of nanoparticles. The authors prepared three sizes of gold nanoparticles AuNPs (15nm, 50nm and 100nm). Vesicles transporting AuNPs were clearly observed in TEM photos, and AuNPs interacted significantly with tumor vascular endothelial cells and were absorbed by the latter, providing direct evidence for transcytosis. Transcytosis is an active metabolic process that requires endothelial cells to rearrange the cytoskeleton and cell membrane, including the formation of vesicles that can absorb nanoparticles, the formation of diaphragms called pore walls, or transport through the cytoplasm. The EPR effect contributed 12%, 3% and 25% to the tumor enrichment of 15nm, 50nm and 100nm gold nanoparticles AuNPs, respectively. This trend is inconsistent with the common perception. Therefore, there may be more complex pathways that affect the EPR effect of 50nm particles. In other words, it is not possible to judge whether the nanoparticles have good tumor penetration ability and are enriched in tumor tissues based solely on their particle size. To explore the distribution, accumulation and penetration ability of nanomedicines of a certain particle size on tumor tissues, technicians need to conduct special research through experiments. Summary of the invention

[0007] There are multiple phenolic hydroxyl groups in the structure of mitoxantrone, and mitoxantrone can form a good coordination with iron ions. In view of this, the inventors used a simple method to synthesize an ultra-small iron ion-coupled mitoxantrone nanoparticle. It has been verified that the nanoparticle has high stability, better tumor targeting, accumulation and distribution than free mitoxantrone drugs, and better tumor penetration and tumor inhibition ability than free mitoxantrone drugs.

[0008] To achieve the above objectives, the present application proposes the following iron ion coupled mitoxantrone nanoparticles and their preparation method, medical use and nanomedicine.

[0009] The invention discloses an iron ion coupled mitoxantrone nanoparticle, which is formed by self-assembly of an iron salt and mitoxantrone or a salt thereof, and the average particle size of the nanoparticle is 40nm.

[0010] Coordination self-assembly is a method that utilizes chemical bonds and non-covalent interactions between molecules to spontaneously assemble molecules into specific structures. In the field of nanomaterials, coordination self-assembly can construct nanostructures with specific shapes, sizes, and functions. In coordination self-assembly, organic molecules or inorganic ions with coordination groups are usually used as building blocks, and through the coordination between them, they self-assemble into nanostructures in solution.

[0011] Metal coordination self-assembly refers to the formation of molecules or supramolecular structures with specific structures and functions under specific conditions through the coordination between metal ions and organic ligands. This method can be used to construct various nanomaterials with specific sizes, shapes and surface properties.

[0012] The building blocks of the present application are selected from iron salts and mitoxantrone or its salts. The iron salts are selected from one or more of ferric chloride, ferric sulfate, and ferric nitrate. Mitoxantrone or its salts are selected from mitoxantrone or mitoxantrone dihydrochloride.

[0013] As a preferred embodiment of the present application, the iron salt is selected from ferric chloride, and mitoxantrone or its salt is selected from mitoxantrone. That is, ferric chloride and mitoxantrone are self-assembled under specific conditions to form iron ion coupled mitoxantrone nanoparticles (referred to as Fe-MIT NPs, further referred to as Fe-MIT).

[0014] As an embodiment of the present application, in the coordination self-assembly, when the iron salt is ferric chloride, its concentration is 5-15 mg / ml, preferably 10 mg / ml; when mitoxantrone or its salt is mitoxantrone, its concentration is 0.3-0.8 mg / ml, preferably 0.5 mg / ml. Within the above concentration range, the iron ion coupled mitoxantrone nanoparticles prepared by the one-pot reaction of ferric chloride and mitoxantrone can be within the appropriate nanoparticle size range, with high atomic utilization, the prepared iron ion coupled mitoxantrone nanoparticles are stable in nature, have excellent drugability, and the tumor targeting, accumulation and distribution of the nanoparticles are better than free drugs. More importantly, the nanoparticles have better tumor penetration and tumor inhibition ability.

[0015] Of course, if the iron salt is selected from ferric sulfate or ferric nitrate, its mass concentration can be converted according to the mass concentration of ferric chloride, and the basis for the conversion is to keep the amount of iron ions in the system the same.

[0016] As an embodiment of the present application, the Fe-MIT NPs nanoparticles provided in the present application have attached Figure 1 The ultraviolet spectrum shown by the middle curve Fe-MIT has an absorption peak at 350nm.

[0017] The present application also provides a method for preparing iron ion-coupled mitoxantrone nanoparticles, comprising the following steps:

[0018] Dissolving mitoxantrone and polyvinyl pyrrolidone in an alcohol solvent to obtain a transparent solution;

[0019] Ferric chloride is dissolved in an alcohol solvent to obtain an alcohol solution of ferric chloride, and then the alcohol solution of ferric chloride is added to the transparent solution to react, thereby obtaining iron ion-coupled mitoxantrone nanoparticles.

[0020] Light can have a significant effect on the formation process of certain self-assemblies. As a preferred embodiment, when the alcohol solution of ferric chloride is added to the transparent solution for reaction, it is carried out under a light-shielding environment. The iron ion-coupled mitoxantrone nanoparticles obtained under light-shielding conditions have a more uniform particle size, have better tumor targeting, accumulation and distribution for patients clinically, and have better tumor penetration ability.

[0021] As a preferred embodiment of the present application, the alcohol solvent is selected from one or more of methanol, ethanol, propanol, isopropanol, and ethylene glycol, preferably ethanol.

[0022] In order to improve the atomic utilization rate and obtain stable iron ion-coupled mitoxantrone nanoparticles with better tumor targeting, accumulation and distribution and better tumor penetration ability, the concentrations of mitoxantrone and polyvinyl pyrrolidone in the above transparent solution are 0.5 mg / ml and 4 mg / ml respectively;

[0023] The concentration of ferric chloride in the above alcoholic solution of ferric chloride is 10 mg / ml;

[0024] The mass ratio of mitoxantrone to ferric chloride is 1:(3-5), preferably 1:4.

[0025] In order to achieve the purpose of providing the iron ions required for the above-mentioned coordination self-assembly, the ferric chloride in the above-mentioned preparation method can also be replaced by ferric sulfate or ferric nitrate, and mitoxantrone can be replaced by mitoxantrone dihydrochloride. The amount of the replacement is determined based on the mass ratio of mitoxantrone to ferric chloride, and the amount of free mitoxantrone and iron ions is kept the same.

[0026] The present application also provides a nanomedicine containing the above-mentioned iron ion-coupled mitoxantrone nanoparticles or the iron ion-coupled mitoxantrone nanoparticles prepared by the above-mentioned preparation method, which is used for treating cancer or tumors.

[0027] As a preferred embodiment of the present application, the nanomedicine treats cancer or tumors by inducing ferroptosis of tumor cells.

[0028] Those skilled in the art should know that, in addition to drugs applied externally or directly administered to the affected area, drugs taken orally or injected are generally transported to the whole body through the blood circulation system after being absorbed by the human body. Tumor tissue has many blood vessels, but the tumor area far from the blood vessels generally has less nutrients available. During drug treatment, the concentration of drugs reaching the tumor area far from the blood vessels is also relatively low.

[0029] Hypoxia is a low oxygen state found in many solid tumors. It is associated with abnormal vascularization of tumors, resulting in reduced oxygen and nutrient supply and impaired drug delivery. The hypoxic nature of tumors also often leads to the development of a local heterogeneous environment, characterized by varying oxygen concentrations, relatively low pH, and elevated levels of reactive oxygen species (ROS). This hypoxic heterogeneity also promotes increased tumor invasion, metastasis, angiogenesis, and drug resistance, all of which greatly reduce the therapeutic efficacy of anticancer drugs. In tumor tissue, areas that are far from blood vessels (deep tumor sites) often show hypoxia.

[0030] Since the iron ion-coupled mitoxantrone nanoparticles provided in the present application have excellent tumor penetration ability, nanomedicines containing the nanoparticles can reach deep tumor tissues / cancer cells, or tumor tissues / cancer cells far away from blood vessels, or tumor tissues / cancer cells in hypoxic areas, and exert an inhibitory effect on tumor cell proliferation.

[0031] As a preferred embodiment of the present application, the above-mentioned cancer or tumor is a cancer or tumor in a hypoxic area.

[0032] As a preferred embodiment of the present application, the above-mentioned cancer or tumor is a cancer or tumor far away from blood vessels.

[0033] "Cancer" refers to leukemias, lymphomas, carcinomas, and other malignancies (including solid tumors) with potentially unrestricted growth that may spread locally by invasion and systemically by metastasis.

[0034] The cancer or tumor is selected from breast cancer, pancreatic cancer, liver cancer, lung cancer, lung cancer, stomach cancer, bone cancer, esophageal cancer, prostate cancer, testicular cancer, colon cancer, ovarian cancer, bladder cancer, cervical cancer, melanoma, meningioma, multiple myeloma, diffuse pleural mesothelioma, leukemia, lymphoma.

[0035] The above-mentioned nano drug, in addition to containing iron ion coupled mitoxantrone nanoparticles, should also add pharmaceutically acceptable adjuvants or excipients according to the characteristics of medicines, drugs, and preparations. The medicine can be any dosage form for clinical use, such as tablets, suppositories, dispersible tablets, enteric-coated tablets, chewable tablets, orodisintegrating tablets, capsules, sugar-coated tablets, granules, dry powders, oral solutions, small needles for injection, injections, freeze-dried powder injections for injection or large infusions. According to the specific dosage form and mode of administration, the pharmaceutically acceptable adjuvants or excipients in the medicine can include one or more of the following: diluents, solubilizers, disintegrants, suspending agents, lubricants, adhesives, fillers, flavoring agents, sweeteners, antioxidants, surfactants, preservatives, encapsulating agents, and pigments, etc.

[0036] The average particle size of the above nano drug is 40nm.

[0037] The present application also provides use of the above-mentioned iron ion-coupled mitoxantrone nanoparticles or the iron ion-coupled mitoxantrone nanoparticles prepared by the above-mentioned preparation method in preparing drugs for treating cancer or tumors.

[0038] As a preferred embodiment of the present application, the iron ion-coupled mitoxantrone nanoparticles treat cancer or tumors by inducing ferroptosis of tumor cells.

[0039] As a preferred embodiment of the present application, the above-mentioned cancer or tumor is a cancer or tumor in a hypoxic area.

[0040] As a preferred embodiment of the present application, the above-mentioned cancer or tumor is a cancer or tumor far away from blood vessels.

[0041] The average particle size of the iron ion coupled mitoxantrone nanoparticles is 40 nm.

[0042] The iron ion coupled mitoxantrone nanoparticles provided in the present application have excellent tumor penetration ability. This may be related to both the EPR effect and transcytosis. The average particle size of Fe-MIT NPs is 40nm. If the particle size is too large, it is not conducive to the transcytosis of the nanoparticles in the tumor tissue layer and affects its diffusion and metastasis, and the tumor penetration ability is poor; if the particle size is too small, it is not conducive to the EPR effect of the nanoparticles and affects its enrichment in the tumor tissue. If the particle size of the nanoparticles is small to a certain extent, it may cause it to pass through the vascular epithelial cells of normal tissues, thereby losing the selectivity / targeting to the tumor tissue. That is to say, if the particle size of the nanoparticles is too large or too small, it will affect the accumulation and distribution of the nanoparticles in the tumor tissue, especially in the deep tumor area, or far away from the blood vessel area, or the tumor tissue in the hypoxic area, that is, the particle size of the nanoparticles is too large or too small, which may show poor tumor penetration and poor selectivity / targeting.

[0043] The nanoparticles with an average particle size of 40 nm provided in the present application have excellent tumor penetration ability. They not only have good accumulation and distribution in the surface tumor site, but also due to their excellent tumor penetration ability, the nanoparticle drug has good accumulation and distribution in the deep tumor site. Therefore, the nanoparticles Fe-MIT NPs with a specific particle size provided in the present application will have a significant enhancement in tumor proliferation inhibition ability under the same drug concentration, and their toxic side effects may be lower, which provides a feasible solution for the treatment of deep tumor tissue / cancer cells, or tumor tissue / cancer cells far away from blood vessels, or tumor tissue / cancer cells in hypoxic areas.

[0044] The words not specifically explained or described in this application text shall be based on the textbooks of medicinal chemistry, organic chemistry, biochemistry and pharmacology. BRIEF DESCRIPTION OF THE DRAWINGS

[0045] Figure 1 UV spectra of Fe-MIT NPs and free MIT;

[0046] Figure 2 Fourier transform infrared spectra (FTIR spectra) of Fe-MIT NPs and free MIT;

[0047] Figure 3 FeCl 3 Comparison of solution, MIT solution, solution before Fe-MIT NPs precipitation, and solid after Fe-MIT NPs precipitation. From left to right, FeCl 3 The colors of solution, MIT solution, solution before Fe-MIT NPs sedimentation, and solid after Fe-MIT NPs sedimentation are yellow, blue, brown, and black, respectively;

[0048] Figure 4 Degradation curves of Fe-MIT NPs under pH 5.5 and pH 7.4, where Drug release (%) indicates the proportion of drug release;

[0049] Figure 5 is the particle size distribution diagram of Fe-MIT NPs, where Particle size represents particle size and Intensity represents intensity;

[0050] Figure 6 Transmission electron microscopy (TEM) image of Fe-MIT NPs, scale bar is 200 nm;

[0051] Figure 7 The curve of particle size change over time of Fe-MIT NPs incubated in PBS and plasma for 48 hours, where Particle size represents particle size;

[0052] Figure 8 It is a bar graph of the hemolysis ratio of red blood cells by Fe-MIT NPs at different concentrations. The vertical axis Hemolysis (%) represents the hemolysis percentage;

[0053] Fig. 9 The fluorescence intensity bar graph representing drug accumulation in MCF-7 cells after incubation with free MIT or Fe-MIT NPs for different time intervals, where Fluorescence intensity represents fluorescence intensity, NPs represents Fe-MIT NPs incubation group, Free drug represents free MIT, and in the three time groups of 2h, 6h and 12h, the left column of each group represents free MIT, and the right column represents Fe-MIT NPs;

[0054] Fig.10 MCF-7 cells were exposed to free MIT, Fe-MIT NPs or Fe 3+ Cell viability curves after 24 h of incubation at different drug concentrations, where Cell viability represents cell viability;

[0055] Fig.11 MCF-7 cells and free MIT drugs, Fe 3+ CLSM fluorescence images reflecting the intracellular ROS levels after incubation with Fe-MIT NPs for different time intervals (6h, 12h), the scale bar is 20μm, where Free drug represents free MIT drug, Fe 3+ FeCl 3 , NPs represents Fe-MIT NPs;

[0056] Fig.12 MCF-7 cells and free MIT drugs, Fe 3+ Immunoblotting of GPX4 protein expression in cells after incubation with Fe-MIT NPs for 12 hours, where Free drug represents free MIT drug, and Fe 3+ FeCl 3 , NPs represents Fe-MITNPs;

[0057] Fig.13 The bar graphs show the in vivo drug concentrations after intravenous injection of free MIT and Fe-MIT NPs at different time intervals (4h, 12h, and 24h), where Free drug represents free MIT drug, and NPs represents Fe-MIT NPs. In the three time groups, the left column of each group represents free MIT drug, and the right column represents Fe-MIT NPs.

[0058] Fig.14 CLSM images of drug intensity and distribution at different time intervals (4 h, 12 h) after intravenous injection of free MIT and Fe-MIT NPs, scale bar is 50 μm, where Free drug represents free MIT, and NPs represents Fe-MIT NPs;

[0059] Fig.15 The penetration CLSM images of free MIT and Fe-MIT NPs at different depths (100 μm, 500 μm, 1000 μm) in the MCTS model, the scale bar is 50 μm, where Free drug represents free MIT, and NPs represents Fe-MIT NPs;

[0060] Fig.16 The graph shows the changes in MCTS volume after incubation with equal concentrations of free MIT and Fe-MIT NPs drugs for different days (day 0, day 2, day 4). The scale bar is 100 μm.

[0061] Fig.17 It is a growth curve of tumor cells in each group of mice in the MCF-7 tumor-bearing mouse model, where Tumorvolume represents tumor volume, Free drug represents free MIT, NPs represents Fe-MIT NPs, and Saline represents normal saline;

[0062] Fig.18 The figure is a curve diagram of the weight changes of mice in each group in the MCF-7 tumor-bearing mouse model, where Tumor volume represents tumor volume, Free drug represents free MIT, NPs represents Fe-MIT NPs, and Saline represents normal saline;

[0063] Fig.19 Pathological (HE) and immunohistochemical (TUNEL) staining images of tumor tissues after different treatments. The scale bar is 50 μm. DETAILED DESCRIPTION

[0064] The present invention is described below with reference to specific examples. It will be appreciated by those skilled in the art that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention in any way.

[0065] The experimental methods in the following examples are conventional methods unless otherwise specified. The medicinal materials, reagents, etc. used in the following examples are commercially available products unless otherwise specified.

[0066] Example 1. Preparation, characterization and physicochemical properties of Fe-MIT NPs

[0067] 1.1 Preparation experiments and characterization

[0068] 25 mg of mitoxantrone (MIT) and 200 mg of polyvinylpyrrolidone (PVP) were added to a 100 mL flask, dissolved in 50 mL of ethanol, and the mixture was sonicated in a water bath to obtain a transparent solution. Then, 100 mg of FeCl 3 Add 10 mL of ethanol and mix FeCl 3 The ethanol solution was added to the transparent solution to initiate the reaction, and the reaction was carried out in a dark environment for 12 hours. After centrifugation (10000rpm, 10min), a black precipitate was obtained, which was Fe-MIT NPs, also referred to as Fe-MIT. Its UV spectrum and FTIR spectrum were tested, and the results were as follows: Figure 1 and Figure 2 shown.

[0069] Figure 1 The UV spectrum showed that the characteristic UV absorption peak of MIT in Fe-MIT NPs disappeared, indicating the synthesis of the new material Fe-MIT NPs. Figure 2 The FTIR spectrum of Fe-MIT NPs showed that the characteristic FTIR peak of MIT was also observed in Fe-MIT NPs, indicating that this new material of nanoparticles contained MIT.

[0070] In the above preparation process, FeCl 3 The free MIT and the Fe-MIT NPs prepared in this application were photographed before and after sedimentation to obtain the following results: Figure 3 Comparison chart shown. Figure 3 Display, Fe 3+ The solution appears yellow, the MIT solution appears blue, the Fe-MIT NPs solution before precipitation appears brown, and the Fe-MIT NPs solid after precipitation appears black. Figures 1 to 3 It shows that the above preparation method successfully obtained Fe-MIT NPs solid particles.

[0071] 1.2 Degradation experiments and TEM imaging

[0072] Fe-MIT NPs were placed in 0.01 mol / L phosphate buffer systems at pH 5.5 and pH 7.4, and the drug release ratios were measured at 0.5, 1, 2, 4, 8, 12, and 24 h, respectively, as follows:

[0073] 1 mL of Fe-MIT NPs (100 μg / mL, prepared in phosphate buffer) was placed in a dialysis bag with a molecular weight cutoff of 3500, placed in 20 mL of phosphate buffer, and oscillated at 37°C. At the set time point, 2 mL of the sample to be tested was taken and supplemented with an equal volume of blank phosphate buffer. The content of the drug (MIT) therein was measured using a fluorescence spectrophotometer, and the proportion of drug release was calculated and plotted into a degradation curve, as shown in FIG. Figure 4 shown.

[0074] The above experiments obtained the degradation curves of Fe-MIT NPs under pH 5.5 and pH 7.4 environments, as shown in Figure 4 As shown, the results show that Fe-MIT NPs are sensitive to acidic environment.

[0075] The particle size of Fe-MIT NPs prepared by the above method was analyzed and detected using a nanoparticle size potential analyzer (ZS90, Malvern, UK). Figure 5 Particle size distribution diagram shown. Figure 5 The results showed that the prepared Fe-MIT NPs were ultra-small nanoparticles with an average particle size distribution of 40 nm. The distribution range of Fe-MIT NPs was narrow and had good dispersibility, which was conducive to the tumor accumulation effect.

[0076] The Fe-MIT NPs prepared by the above method were imaged using a transmission electron microscope (TEM, Tecnai G2 F30, FEI, USA). Figure 6 The scale bar of the transmission electron micrograph shown is 200 nm. Figure 6 It shows that the Fe-MIT NPs nanoparticles are uniform in size and evenly distributed.

[0077] 1.3 Stability test

[0078] Existing technologies show that the stability of nanoparticle drugs can significantly affect or even change their absorption and metabolism in the body.

[0079] In order to reveal the stability of Fe-MIT NPs, Fe-MIT NPs were incubated in phosphate buffered saline (PBS) or plasma at a specific concentration and their size was monitored for 48 hours. The PBS used in the experiment simulates the physiological pH of the human body and can reveal the effect of physiological pH on the size of Fe-MIT NPs, while plasma can reflect the size changes of Fe-MIT NPs when they interact with complex blood components.

[0080] The Fe-MIT NPs were incubated in the above phosphate buffer and plasma for 48 h, respectively. The particle sizes of the Fe-MIT NPs were detected using a nanoparticle size potentiometer (ZS90, Malvern, UK) at 3 h, 6 h, 9 h, 12 h, 24 h, 36 h, and 48 h, respectively, and plotted as shown in the figure. Figure 7 The particle size variation curve is shown.

[0081] The above experiment obtained the curve of particle size change over time of Fe-MIT NPs incubated in PBS and plasma for 48 hours, as shown in Figure 7 As shown in the figure, the results show that Fe-MIT NPs incubated in PBS and plasma for 48 hours, and the particle size changes are very small. The experiment shows that the stability of Fe-MIT NPs is not significantly affected by physiological pH and complex blood components, indicating that Fe-MIT NPs can be used as a stable in vivo drug and is expected to be prepared as a nano drug.

[0082] 1.4 Hemolytic safety test

[0083] After confirming that Fe-MIT NPs have good stability, the inventors further explored the safety of Fe-MIT NPs.

[0084] The inventors used a hemolysis test to study whether Fe-MIT NPs damage red blood cells. Nanoparticles of different concentrations were incubated with 2% mouse red blood cells (Solarbio, China) for 1 hour, then centrifuged and the hemoglobin leakage was detected and analyzed to evaluate the damage to red blood cells. The specific experimental process and post-processing operations are as follows:

[0085] Fe-MIT NPs were prepared into 0.1 mg / mL, 0.2 mg / mL, 0.4 mg / mL, 0.6 mg / mL, and 0.8 mg / mL test solutions using 0.01 mol / L phosphate buffer, and incubated with mouse erythrocytes for 1 h, respectively. The absorbance of the supernatant at 590 nm was detected for erythrocytes, and the proportion of hemolysis was calculated and plotted as shown in the figure. Figure 8 Hemolysis ratio bar graph shown.

[0086] The above experiment obtained a bar graph of the hemolysis ratio of red blood cells by Fe-MIT NPs at different concentrations, such as Figure 8As shown, the results show that Fe-MIT NPs at a concentration of 0.1 mg / mL only cause about 0.5% hemolysis on red blood cells, and Fe-MIT NPs at a concentration of 0.8 mg / mL only cause about 2% hemolysis on red blood cells. In fact, the dose administered in vivo is usually at the microgram level, which is much lower than the 0.1 mg / mL level in the experiment. The above experimental results show that Fe-MIT NPs provide solid evidence for the safety of red blood cells.

[0087] After demonstrating the stability and safety of Fe-MIT NPs, the inventors further studied the cellular uptake behavior of Fe-MIT NPs in breast cancer cell lines and explored the inhibitory effect of Fe-MIT NPs on tumor cell proliferation compared with free drugs, that is, the comparison of tumor cell toxicity.

[0088] Example 2: Study on drug accumulation of free MIT and Fe-MIT NPs in MCF-7 cells and their anticancer effects in vitro

[0089] MCF-7 cells are a type of human breast cancer cell.

[0090] MCF-7 cells with a confluence of 70% in a 96-well plate were incubated with free MIT or Fe-MIT NPs (2 μg / mL, prepared in DMEM medium containing various amino acids and glucose) for 12 h, and the fluorescence signal intensity of MIT in the cells was detected at 2 h, 6 h, and 12 h. Since MIT is a fluorescent molecule, the fluorescence signal intensity of MIT in the cells can be measured using a fluorescence microplate reader (VarioskanLUX, Thermo-Fisher, USA, Ex = 490 nm, Em = 580 nm) to quantify the drug accumulation in the cells.

[0091] The above experiment obtained the fluorescence intensity bar graph indicating drug accumulation in MCF-7 cells after incubation of free MIT or Fe-MIT NPs for different time intervals, as shown in Fig. 9 As shown in the figure, Free Drug represents free MIT, and NPs represents Fe-MIT NPs. Fig. 9The experimental results showed that the drug accumulation and retention of Fe-MIT NPs and free MIT in MCF-7 cells were positively correlated, and the accumulation of Fe-MIT NPs was higher than that of free MIT throughout the test. The experimental results show that Fe-MIT NPs may have better accumulation and / or retention effects than free MIT, thereby improving the effect of inhibiting tumor proliferation. This result may be related to the fact that nanoparticles can enter cells through cellular endocytosis. In addition, when drugs are encapsulated in nanoparticles, they can also bypass protective mechanisms such as the efflux effect of cancer cells. The above results show that Fe-MITNPs may have better tumor proliferation inhibition than free MIT.

[0092] In order to verify that Fe-MIT NPs have better tumor proliferation inhibition effect than free MIT, free MIT or Fe-MIT NPs at different specified concentrations (0.2, 0.5, 0.75, 1.0, 1.5, 2.0 μg / mL (prepared with DMEM medium, DMEM medium contains various amino acids and glucose) were incubated with cells for 24 hours, and then the MTT method (MTT method, also known as MTT colorimetry, is a method for detecting cell survival and growth. The detection principle is that succinate dehydrogenase in the mitochondria of living cells can reduce exogenous MTT to water-insoluble blue-purple crystalline formazan (Formazan) and deposit in the cells, while dead cells do not have this function. Within a certain range of cell numbers, the amount of MTT crystals formed is proportional to the cell number) was used to evaluate cell viability.

[0093] The above experiments obtained MCF-7 cells and free MIT, Fe-MIT NPs or Fe 3+ Cell viability curves after 24 h of incubation at different drug concentrations, such as Fig.10 shown. Fig.10 The experimental results showed that when the drug concentration was lower than 0.75 μg / mL, free MIT and Fe-MIT NPs showed similar cytotoxicity to MCF-7 cells. When the drug concentration exceeded 0.75 μg / mL, the cytotoxicity of Fe-MIT NPs exceeded that of free MIT. Moreover, as the concentration increased, the gap between the cytotoxicity of Fe-MIT NPs and free MIT gradually increased. 3+ The experimental results showed that using Fe-MIT NPs as a delivery platform, the drug could accumulate at a high level in MCF-7 cells, and also enhanced its inhibitory effect on breast cancer cell proliferation.

[0094] The above studies show that Fe-MIT NPs have better accumulation and / or retention effects in MCF-7 cells than free MIT, and also have better tumor proliferation inhibition effects. There are a large number of iron ions in Fe-MIT NPs. The inventors speculate that after the internalization of Fe-MIT NPs, iron overload-induced ferroptosis may occur. Ferroptosis is an iron-dependent cell death that is usually associated with increased levels of intracellular reactive oxygen species (ROS).

[0095] Example 3: Study on the Level of Reactive Oxygen Species (ROS) and Ferroptosis in MCF-7 Cells

[0096] Dichlorodihydrofluorescein (DCFH, 2`,7`-dichlorodihydrofluorescein) is a fluorescent probe for measuring reactive oxygen species. When oxidized by ROS to 2',7'-dichlorofluorescein hydride probe (DCF), it emits strong fluorescence. The interaction between ROS and dichlorodihydrofluorescein (DCFH) produces green fluorescence in a concentration-dependent manner. DCFH has good lipid solubility and membrane permeability, so it is widely used in the detection of intracellular ROS.

[0097] MCF-7 cells with a confluence of 70% in 24-well plates were incubated with free MIT, FeCl 3 or Fe-MIT NPs (free MIT and Fe-MIT NPs were 2 μg / mL, FeCl 3 The cells were incubated for 6 and 12 hours at 1 μg / mL (prepared with DMEM medium containing various amino acids and glucose). 0.5 hours before the selected time point, the cells were preloaded with the ROS probe DCFH-DA (Beyotime, China) according to the product instructions. Afterwards, the intracellular ROS level was visualized using a confocal laser scanning microscope (CLSM, LSM900, Zeiss, Germany).

[0098] The above experiments obtained MCF-7 cells and free MIT drugs, Fe 3+ CLSM fluorescence images reflecting the intracellular ROS levels after incubation with Fe-MIT NPs for different time intervals (6h, 12h), as shown in Fig.11 As shown, the scale bar is 20 μm. Fig.11 The experimental results showed that after 6 hours of incubation, the free MIT drug group (Free Drug) and the iron group (Fe 3+) showed only a weak intracellular fluorescence signal, indicating that the intracellular ROS level was low. In contrast, the fluorescence signal of the NPs group (Fe-MIT NPs) was more obvious, indicating that the ROS level was relatively high. When the time was extended to 12h, this phenomenon was more obvious, and a strong fluorescence signal could be observed in MCF-7 cells. The significant increase in intracellular ROS levels strongly suggests that MCF-7 cells have a high potential for ferroptosis.

[0099] GPX4 is a glutathione peroxidase that plays an important antioxidant role in cells. GPX4 can convert harmful oxides such as hydroperoxides and organic peroxides into corresponding alcohols and water, thereby protecting cells from oxidative stress. GPX4 plays a key role in maintaining intracellular redox balance and cell survival. GPX4 protein is the cornerstone of anti-peroxide defense in cells, and a large amount of ROS caused by ferroptosis can significantly inhibit the expression of GPX4.

[0100] After 12 hours of incubation in the above experiment, the cells were collected and the levels of ferroptosis-related antioxidant enzyme glutathione peroxidase 4 (GPX4) in different groups were determined by western blotting, and GADPH (lysine aldehyde-3-phosphate dehydrogenase) was used as a control protein. The experimental process is as follows:

[0101] After the MCF-7 cells were collected, the whole cell protein was extracted using cell lysis buffer. The extracted protein was separated by 10% polyacrylamide gel electrophoresis with a loading amount of 20 μg per well. After separation, the protein was transferred from the gel to a polyvinylidene fluoride (PVDF) membrane. The primary antibodies of GPX4 and GADPH were incubated with the membrane at 4°C overnight, and then incubated with the corresponding horseradish peroxidase-labeled secondary antibodies for 2 hours. Finally, a chemiluminescence kit was used for color development, and an exposure instrument was used to take pictures and record.

[0102] The above experiments obtained MCF-7 cells and free MIT drugs, Fe 3+ Immunoblotting images of GPX4 protein expression in cells after incubation with Fe-MIT NPs for 12 h. Fig.12 shown. Fig.12 The experimental results showed that the expression level of GPX4 protein in the NPs group was the lowest, indicating the highest level of ferroptosis, which also confirmed Fig.11 The experimental results. Fig.11 and Fig.12 The experimental results not only confirm that Fe-MIT NPs have a strong ability to induce ferroptosis, but also provide a new perspective for the potential of Fe-MIT NPs in inducing ferroptosis compared with free MIT and Fe 3+ The superior inhibitory effect on tumor proliferation in vitro provides another explanation.

[0103] The inventors have confirmed through the above studies that Fe-MIT NPs are more effective than free drugs and Fe 3+ The drug has an enhanced in vitro tumor growth inhibition effect. However, in vivo, Fe-MIT NPs have a stronger inhibitory effect on tumor growth than free drugs and Fe 3+ Whether it still has an enhanced tumor growth inhibition effect, and whether it can have a good accumulation and distribution in tumor tissue to produce tumor targeting. In addition, whether it can produce a positive tumor growth inhibition effect in the hypoxic area of ​​the tumor. The inventors further explored the following.

[0104] Example 4: In vivo tumor targeting, distribution and penetration of Fe-MIT NPs

[0105] 4.1 Tumor targeting and drug distribution studies

[0106] The MCF-7 tumor-bearing mouse model was established, and all animal experiments were approved by the Animal Ethics Committee of Wuhan Hualianke Biotechnology Co., Ltd.

[0107] The mice were divided into groups and free MIT or Fe-MIT NPs (MIT concentration: 5 mg / kg) were injected into the tumor model mice via tail vein. At the specified time point, the MIT content in the tumor tissue of the mice (n=3) was measured to determine the concentration of MIT contained. In addition, the tumor tissue was collected and micro-cut, and the intensity and distribution of MIT in the tumor were observed using a confocal laser scanning microscope (CLSM). The specific method is as follows:

[0108] Tumor-bearing mice were randomly divided into two groups, with 9 animals in each group. Free MIT and Fe-MIT NPs (MIT dosing concentration: 5 mg / kg) were respectively administered to tumor model mice by tail vein injection. Three mice were killed at designated time points (4h, 12h, 24h), and their tumors were removed. The tumor was evenly dispersed in 2mL of drug extract (a solution with a volume ratio of 1:1 between ethanol and 0.6mol / L hydrochloric acid) using a tissue homogenizer and allowed to stand for 24h to fully extract the drug. The liquid was then centrifuged at 15,000 rpm for 10 minutes, and the supernatant was used to detect the drug (MIT) content. The drug content was plotted against time to obtain Fig.13 In parallel, the tumor tissue was immersed in an appropriate amount of OCT embedding medium, placed in a small cup filled with liquid nitrogen, and frozen into a solid. The slices were sliced ​​using a freezing microtome (10 μm). The slices were placed on a slide, stained with DAPI dye (10 minutes), and then sealed with a coverslip. The CLSM was used for observation and the results were recorded. Fig.14 .

[0109] The above experiment obtained the in vivo drug concentration bar graph after intravenous injection of free MIT and Fe-MIT NPs at different time intervals (4h, 12h, 24h), as shown in Fig.13 shown. Fig.13 The experimental results show that at 4h, 12h, and 24h, the in vivo concentration of free MIT is much lower than that of Fe-MITNPs, and in the first 4h, the concentration of free MIT is extremely low, and the concentration accumulates slowly as time goes by. In contrast, Fe-MIT NPs have a relatively high concentration in the first 4h, and the concentration increases rapidly as time goes by. The experimental results show that at different time points after injection, the targeting and retention of free MIT in tumor tissue are much worse than those of Fe-MIT NPs. Moreover, this difference becomes greater as time goes by. This may be because free MIT has no targeting effect and can be distributed throughout the body through blood circulation, resulting in its poor retention ability for tumor tissue; free MIT usually has a short half-life and can be cleared from the body in a short time. In contrast, Fe-MIT NPs as nanoparticles show enhanced tumor accumulation, which may be related to the high permeability and high retention of Fe-MIT NPs.

[0110] The above experiments obtained CLSM images of drug intensity and distribution at different time intervals (4h, 12h) after intravenous injection of free MIT and Fe-MIT NPs, as shown in Fig.14 As shown, the scale bar is 50 μm. Fig.14 The experimental results showed that the drug intensity of the free MIT group (FreeDrug) in tumor tissue was lower, and the MIT signal of the Fe-MIT NPs group (NPs) was stronger than that of the free MIT group at 4h and 24h. In addition, the drug signal distribution of the Fe-MIT NPs group also covered a wider area in the tumor tissue, indicating that Fe-MIT NPs were better distributed in the tumor tissue, further confirming that Fe-MIT NPs had better tumor cell proliferation inhibition ability than free MIT.

[0111] 4.2 Tumor tissue penetration study

[0112] The inventors have proved through the above studies that Fe-MIT NPs have better targeting and accumulation capabilities in tumor tissues, and Fe-MIT NPs have better distribution in tumor tissues. The ability of a drug to penetrate tumor tissues is one of the important considerations for evaluating drug efficacy, because poor tumor penetration is usually associated with poor anti-cancer results, especially for tumor cells in hypoxic areas. Due to various reasons such as drug delivery, the drug concentration in hypoxic areas is often relatively low. Therefore, the inventors further revealed the tumor penetration effect of Fe-MIT NPs and studied the reasons why the nanomedicines prepared in this application have better accumulation and distribution in tumor tissues.

[0113] To eliminate interference, the inventors established a multicellular tumor spheroid (MCTS) model to simulate solid tumors in vivo and evaluated the penetration potential of Fe-MIT NPs and free MIT at the same drug concentration.

[0114] Multicellular tumor spheroids (MCTS) were established and incubated with free MIT or Fe-MIT NPs (2 μg / mL) for 4 days. MCTS were imaged using CLSM at the indicated time points.

[0115] MCTS were randomly divided into two groups. After being incubated with free MIT and Fe-MIT NPs (2 μg / mL) for 1 day, the fluorescence signal intensity of MIT at different levels of MCTS was recorded using the tomography function of CLSM.

[0116] The above experiments obtained the penetration CLSM images of free MIT and Fe-MIT NPs at different depths (100 μm, 500 μm, 1000 μm) in the MCTS model, as shown in Fig.15 As shown, the scale bar is 50 μm. Fig.15 The experimental results show that the fluorescence signal of the NPs group at the same depth is much higher than that of the free MIT group. The experimental results show that at the same drug concentration, the tumor penetration ability of Fe-MIT NPs (NPs group) is significantly better than that of the free MIT drug (Free Drug group), that is, the nanoparticles prepared in this application have excellent tumor penetration ability.

[0117] This may be related to both the EPR effect and transcytosis. The average particle size of Fe-MIT NPs is 40nm. If the particle size is too large, it is not conducive to the transcytosis of nanoparticles in the tumor tissue layer, affecting its diffusion and metastasis, and poor tumor penetration; if the particle size is too small, it is not conducive to the EPR effect of nanoparticles and affects their enrichment in tumor tissues. If the particle size of nanoparticles is small to a certain extent, it may lead to good permeability in the vascular epithelial cells of normal tissues, thereby losing selectivity / targeting to tumor tissues. In other words, if the particle size of nanoparticles is too large or too small, it will affect the accumulation and distribution of nanoparticles in tumor tissues, especially in deep tumor areas, or far away from blood vessels, or tumor tissues in hypoxic areas. That is, if the particle size of nanoparticles is too large or too small, it may show poor tumor penetration and poor selectivity / targeting.

[0118] The above experiments show that the nanoparticles with an average particle size of 40 nm provided in the present application have excellent tumor penetration ability. They not only have good accumulation and distribution in the surface tumor site, but also due to their excellent tumor penetration ability, the nanoparticle drug has good accumulation and distribution in the deep tumor site. Therefore, the nanoparticles Fe-MIT NPs with a specific particle size provided in the present application will have a significant enhancement in tumor proliferation inhibition ability under the same drug concentration, and their toxic side effects may be lower, which provides a feasible clinical solution for the treatment of deep tumor tissue / cancer cells, or tumor tissue / cancer cells far away from blood vessels, or tumor tissue / cancer cells in hypoxic areas.

[0119] 4.3 Study on tumor proliferation inhibition in MCTS model

[0120] After confirming that Fe-MIT NPs have better targeting, retention, distribution and penetration capabilities for both superficial and deep tumors, the inventors further studied the anticancer effects of Fe-MIT NPs and free MIT drugs in vivo. MCTS was used as a model. Specifically, MCTS was incubated with the same concentration of free MIT or Fe-MIT NPs for 4 days, and its volume was monitored every two days.

[0121] MCTS were randomly divided into two groups. After incubation with free MIT and Fe-MIT NPs (2 μg / mL) for 4 days, the volume size of MCTS was recorded using a microscope on days 0, 2, and 4.

[0122] The above experiment obtained the change diagram of MCTS volume after incubation of equal concentrations of free MIT and Fe-MIT NPs drugs for different days (day 0, day 2, day 4), as shown in Fig.16 As shown, the scale bar is 100 μm. Fig.16 The experimental results showed that at a given drug concentration, the MCTS volume of the MIT-administered group gradually increased, while the MCTS volume of the Fe-MIT NPs-administered group gradually decreased. The experimental results showed that MIT could not completely inhibit the growth of MCTS, which caused the MCTS volume on day 4 to increase compared to day 0, which may be due to the poor MIT drug retention capacity and intercellular permeability in tumor cells. In contrast, Fe-MIT NPs have better intracellular drug retention and intercellular permeability, and the drug can successfully reach deep tumor cells and exert an anti-tumor effect. At the end of the experiment, it successfully inhibited the proliferation of MCTS and reduced tumor volume. Therefore, the nanoparticles Fe-MIT NPs provided in this application provide a feasible option for treating cancer or tumors in hypoxic areas.

[0123] Example 5: In vivo tumor proliferation inhibition test and HE and TUNEL staining test in animals

[0124] 5.1 In vivo tumor proliferation inhibition test in animals

[0125] Nude Balb / c mice were used to establish an MCF-7 tumor-bearing mouse model. The mice were divided into groups and injected with tumors (100-200 mm 3 The tumor volume of mice was recorded before administration.

[0126] The tumor-bearing mice were randomly divided into two groups, with 3 animals in each group. The two groups of tumor models (100-200 mm 3 The tumor volume was calculated by PCR. The tumor volume was recorded using a vernier caliper before each administration, and a time-tumor volume relationship graph was plotted to obtain the tumor volume. Fig.17 The tumor cell growth curve was obtained by using a balance to record the weight of the mice and plotting the relationship between time and mouse weight. Fig.18 Body weight change curve of mice.

[0127] The above experiment obtained the tumor cell growth curves of the control group (normal saline), free MIT (Free Drug) and Fe-MIT NPs experimental group, as shown in Fig.17 shown. Fig.17 The experimental results showed that at each time point, the tumor cell volume in the Fe-MIT NPs group was smaller than that in the free MIT and control groups, and the data in each group were significant. The experimental results showed that compared with free MIT drugs, Fe-MIT NPs had a better tumor proliferation inhibition effect.

[0128] The above experiment obtained the weight change curves of mice in the control group (normal saline), free MIT (Free Drug) and Fe-MIT NPs experimental groups, as shown in Fig.18 shown. Fig.18 The experimental results showed that the weight of mice in the control group and Fe-MIT NPs did not decrease significantly during the experiment, while the weight of mice in the free MIT group decreased significantly at the end of the experiment, which may be due to the cytotoxicity caused by the non-targeted distribution of free MIT.

[0129] The above experimental results further confirmed the experimental conclusions in Examples 4.2 and 4.3 that Fe-MIT NPs have good tumor targeting, accumulation, distribution and safety.

[0130] 5.2 HE and TUNEL staining assay

[0131] HE staining, also known as hematoxylin-eosin staining, in which hematoxylin is Hematoxylin, referred to as H, and eosin is Eosin, referred to as E. This is a staining method for observing and distinguishing cell apoptosis and cell necrosis under ordinary optical microscope.

[0132] TUNLE staining is the in situ terminal transferase labeling technique. The DNA double strands of apoptotic cells are broken or one strand is nicked, resulting in a series of 3'-OH ends. Under the action of terminal deoxyribonucleotide transferase (TdT), the derivatives formed by deoxyribonucleotides and biotin are labeled to the 3' end of DNA, thereby detecting apoptotic cells. TUNLE staining is a research method that combines molecular biology with morphology. It can accurately reflect the most typical biochemical and morphological characteristics of apoptotic cells by in situ staining of intact single apoptotic cell nuclei or apoptotic bodies.

[0133] At the end of the experimental determination in 5.1, tumor tissues from different groups were collected and subjected to HE and TUNEL staining. The experimental method is as follows:

[0134] Tumor tissue pretreatment

[0135] Fixation: Tumor tissues were placed in 4% formaldehyde solution at 4°C overnight.

[0136] Dehydration: The fixed tumor tissue was dehydrated step by step with graded ethanol, soaked in 60%, 70%, 80%, 90%, 95%, and 99% ethanol for one hour each, and then soaked in anhydrous ethanol twice, each time for one hour.

[0137] Transparency: The dehydrated tumor tissue was transparentized in xylene twice, each time for half an hour.

[0138] Wax immersion: Immerse the tumor tissue in 65°C liquid wax three times, each time for one hour.

[0139] Embedding: After wax immersion, embed the tumor tissue at a wax temperature of 68°C.

[0140] Sectioning: Sectioning was performed along the direction of the maximum cross section, and the thickness of each section was 5 μm.

[0141] Paraffin sections were stored at room temperature. Before using them, they were baked at 60°C for 2 hours.

[0142] HE staining steps:

[0143] 1) Hematoxylin staining for 5 minutes;

[0144] 2) Rinse with distilled water for 3 minutes;

[0145] 3) Differentiation with 1% hydrochloric acid and ethanol for 15 seconds until the blue color fades;

[0146] 4) Rinse with distilled water for 3 minutes;

[0147] 5) Eosin staining for 5 seconds;

[0148] 6) Wash with PBS for 1-2 seconds;

[0149] 7) Soak in 70% ethanol for 2 minutes;

[0150] 8) Soak in 80% ethanol for 2 minutes;

[0151] 9) Soak in 90% ethanol for 2 minutes;

[0152] 10) Soak in 95% ethanol for 2 minutes;

[0153] 11) Soak in anhydrous ethanol for 2 minutes;

[0154] 12) Soak in anhydrous ethanol for 2 minutes;

[0155] 13) Soak in xylene for 5 minutes;

[0156] 14) Soak in xylene for 5 minutes;

[0157] 15) Seal with neutral resin.

[0158] Use a microscope to take photos of the HE-stained sections. Fig.19 As shown in the HE group.

[0159] TUNEL staining steps:

[0160] 1) Incubate Streptavidin-HRP solution at 37°C for 30 min in dark;

[0161] 2) Wash with 1*PBS for 5 min*3 times;

[0162] 3) DAB color development;

[0163] 4) Wash with 1*PBS for 5 min*3 times;

[0164] 5) After counterstaining with hematoxylin, the slides were processed and sealed.

[0165] Use a microscope to take photos, such as Fig.19 The TUNEL group is shown.

[0166] The above experiments obtained pathological (HE) and immunohistochemical (TUNEL) staining images of tumor tissues after different treatments, such as Fig.19As shown, the scale bar is 50 μm. The results showed that the control group showed the characteristic structure of malignant tumors, with massive cell proliferation, tight connections, and low apoptosis levels (low levels of TUNEL-positive cells). In contrast, after treatment with free MIT and Fe-MITNPs, loose structural changes can be seen, that is, cells suffered a higher apoptosis ratio. Among them, the damage to the cell apoptosis structure and apoptosis level in the Fe-MIT NPs group was more obvious than that in the free drug group, suggesting that Fe-MIT NPs have a strong anti-cancer effect.

[0167] The present application proposes a simple one-pot method for synthesizing ultra-small iron ion-coupled mitoxantrone nanoparticles (Fe-MIT NPs), which are composed of particles of about 40nm and have high stability. In vitro cell experiments using MCF-7 cells showed that intracellular drugs had better accumulation and better in vitro anticancer effects, which may be related to the combination of chemotherapy and ferroptosis. In addition, the present application also demonstrated that Fe-MIT NPs showed better tumor targeting, accumulation and distribution than free drugs in the MCF-7 tumor-bearing mouse model. The MCTS model further revealed that Fe-MIT NPs have good tumor penetration and tumor suppression ability, that is, the Fe-MIT NPs with an average particle size of 40nm provided in the present application not only have good targeting, accumulation and distribution in the surface tumor site, but also have good targeting, accumulation and distribution in the deep tumor site. This provides a feasible option for the treatment of deep tumor areas such as hypoxia or cancer cells away from blood vessels. Finally, the in vivo anticancer properties of Fe-MIT were investigated using an MCF-7 tumor-bearing mouse model, and the results showed that Fe-MIT NPs had better tumor inhibition and safety than free MIT.

[0168] The specific embodiments described above further illustrate the objectives, technical solutions and beneficial effects of the present invention in detail. It should be understood that the above are only specific embodiments of the present invention and are not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of this application should be included in the protection scope of this application.

Claims

1. An iron ion coupled mitoxantrone nanoparticle, It is characterized in that The nanoparticles are formed by self-assembly of iron salt and mitoxantrone or its salt, and the average particle size of the nanoparticles is 40 nm.

2. The nanoparticle according to claim 1, in, The iron salt is selected from one or more of ferric chloride, ferric sulfate, and ferric nitrate, preferably ferric chloride; The mitoxantrone or its salt is selected from mitoxantrone or mitoxantrone dihydrochloride, preferably mitoxantrone.

3. The nanoparticle according to claim 1, in, In the coordination self-assembly, the concentration of the iron salt is 5-15 mg / ml, preferably 10 mg / ml, and the concentration of mitoxantrone or its salt is 0.3-0.8 mg / ml, preferably 0.5 mg / ml; or The nanoparticles have an ultraviolet spectrum shown by the curve Fe-MIT in FIG1 .

4. A method for preparing iron ion coupled mitoxantrone nanoparticles, comprising the following steps: Dissolving mitoxantrone and polyvinyl pyrrolidone in an alcohol solvent to obtain a transparent solution; Ferric chloride is dissolved in an alcohol solvent to obtain an alcohol solution of ferric chloride, and then the alcohol solution of ferric chloride is added to the transparent solution to react, thereby obtaining iron ion-coupled mitoxantrone nanoparticles.

5. The preparation method according to claim 4, in, The reaction of adding the alcohol solution of ferric chloride into the transparent solution is carried out under a light-shielding environment; or The alcohol solvent is selected from one or more of methanol, ethanol, propanol, isopropanol, and ethylene glycol, preferably ethanol.

6. The preparation method according to claim 4, in, The concentrations of mitoxantrone and polyvinyl pyrrolidone in the transparent solution are 0.5 mg / ml and 4 mg / ml respectively; or The concentration of ferric chloride in the alcohol solution of ferric chloride is 10 mg / ml; or The mass ratio of mitoxantrone to ferric chloride is 1:(3-5), preferably 1:

4.

7. A nanomedicine containing the iron ion coupled mitoxantrone nanoparticles according to any one of claims 1 to 3 or the iron ion coupled mitoxantrone nanoparticles prepared by the preparation method according to any one of claims 4 to 6, which is used for treating cancer or tumor.

8. The nano drug according to claim 7, in, The nanomedicine treats cancer or tumors by inducing ferroptosis of tumor cells; or The cancer or tumor is a cancer or tumor in a hypoxic region; or The cancer or tumor is a cancer or tumor that is far from a blood vessel; or The cancer or tumor includes breast cancer, pancreatic cancer, liver cancer, lung cancer, lung cancer, stomach cancer, bone cancer, esophageal cancer, prostate cancer, testicular cancer, colon cancer, ovarian cancer, bladder cancer, cervical cancer, melanoma, meningioma, multiple myeloma, diffuse pleural mesothelioma, leukemia, lymphoma; or The nanomedicine further contains pharmaceutically acceptable auxiliary materials or excipients; or The average particle size of the nano drug is 40 nm.

9. Use of the iron ion coupled mitoxantrone nanoparticles according to any one of claims 1 to 3 or the iron ion coupled mitoxantrone nanoparticles prepared by the preparation method according to any one of claims 4 to 6 in preparing a drug for treating cancer or tumor.

10. The use according to claim 9, in, The iron ion-coupled mitoxantrone nanoparticles treat cancer or tumors by inducing ferroptosis of tumor cells; or The cancer or tumor is a cancer or tumor in a hypoxic region; or The cancer or tumor is a cancer or tumor that is far from a blood vessel; or The cancer or tumor includes breast cancer, pancreatic cancer, liver cancer, lung cancer, lung cancer, stomach cancer, bone cancer, esophageal cancer, prostate cancer, testicular cancer, colon cancer, ovarian cancer, bladder cancer, cervical cancer, melanoma, meningioma, multiple myeloma, diffuse pleural mesothelioma, leukemia, lymphoma.